Topic summary

Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes

Compounds › Oral incretins randomised trial SOUL trial oral semaglutide orforglipron PIONEER programme Solved

This is a generated summary. It shows the 9 most-liked posts from a topic of 105, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.wojcikTL24 May 2025#1

The SOUL trial and oral semaglutide cardiovascular outcomes — setting out what I have, and where I think it stops being reliable.

SOUL trial and oral semaglutide — I have the observation and I do not trust my interpretation of it, so I am posting the observation and holding the interpretation back.

Numbers, method and the conditions under which they were collected are below. Interpret them however they warrant.

42 likes 15mo

cohort_watchTL2Member Solution1 Jun 2025 · edited#6

baseline_table, post #2: Confirming the opening post from a second method, which matters more than confirming it from a second person. PIONEER 6 is the cardiovascular outcome trial for oral semaglutide and it enrolled a diabetes population at high cardiovascular risk. Quoting it outside that population is an extrapolation. Go to post

The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.

6 likes in reply to #2 14mo

vial_deskTL3Regular16 Jul 2025#18

a.coelho, post #7: Worth separating two things that post #3 runs together. Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak. Go to post

Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.

I am reporting what happened, not recommending it.

30 likes in reply to #7 12mo

a.iyerTL24 Aug 2025 · edited#24

That is a cleaner way of putting what I was circling around.

26 likes 12mo

r.serranoTL28 Sep 2025#36

n.boateng, post #26: Confirming post #23 from a second method, which matters more than confirming it from a second person. Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not… Go to post

Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.

28 likes in reply to #26 11mo

y.ibarraTL214 Oct 2025#49

That reframing is the whole thing. The facts I already had.

28 likes 9mo

e.ferreiraTL3Regular6 Nov 2025#58

Noted, and thank you for writing it out rather than summarising it.

31 likes in reply to #2 9mo

s.girardTL29 Jan 2026 · edited#84

This follows post #81 rather than contradicting it.

Taking the oral product with more water than instructed reduces absorption rather than helping it. That is counter-intuitive and it is one of the few dosing instructions in this field with a clear pharmacokinetic basis.

31 likes 7mo

n.stanescuTL212 Feb 2026 · edited#99

PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.

32 likes 5mo

Read the full topic (105 posts)

This topic was referenced in

Revisiting: Food effects on oral incretin absorption: what is documentedCompounds › Oral incretins · 10 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Orforglipron as a non-peptide: what changes when the molecule is small Compounds › Oral incretins orforglipron SOUL trial PIONEER programme On the subject in the title: Orforglipron as a non-peptide: what changes when the molecule is small Working notes rather than a conclusion. What changes if the standard account of orforglipron is wrong? I ask…	+26	30	26k	23mo
SNAC and the mechanism of oral peptide absorption Compounds › Oral incretins orforglipron randomised trial PIONEER programme oral semaglutide On the subject in the title: SNAC and the mechanism of oral peptide absorption Working notes rather than a conclusion. A comparison question rather than a question about one compound. Two things in the same…	+13	17	14k	17mo
Dose numbers for oral formulations are not comparable to injectable ones Compounds › Oral incretins orforglipron PIONEER programme SOUL trial On the subject in the title: Dose numbers for oral formulations are not comparable to injectable ones Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a…	+19	23	39k	6mo
About the Oral incretins category Compounds › Oral incretins oral semaglutide orforglipron PIONEER programme Pinned Wiki Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	6.2k	20d
Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Compounds › Oral incretins randomised trial oral semaglutide SOUL trial PIONEER programme Posting this under the heading it deserves: Oral versus injectable exposure: comparing apples to a different fruit — a second dataset Everything below is what sits behind that. Something about Oral versus…	+27	31	17k	25d

Related topics — sharing the tags randomised trial, SOUL trial, oral semaglutide

Topic	Participants	Replies	Views	Activity
About the Oral incretins category Compounds › Oral incretins oral semaglutide orforglipron PIONEER programme Pinned Wiki Oral semaglutide, orforglipron and the absorption problem. PIONEER and OASIS data. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…		4	6.2k	20d
Coming back to: Why semaglutide solutions can look faintly opalescent and when that matters Compounds › Semaglutide SELECT trial randomised trial STEP programme Asking directly, because I could not find a straight answer: Why semaglutide solutions can look faintly opalescent and when that matters Reading back through what has been written here about semaglutide…	+16	20	17k	13mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial Wiki On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. A comparison question rather than a question about one…	+2	6	2.4k	7mo
What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide STEP programme type 2 diabetes randomised trial Solved Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not I was wrong about SELECT in a thread last spring and I would like to…	+120	132	2k	14mo
Second pass at: Reading a trial's population section before its results Evidence › Trials open label intention to treat estimand surrogate endpoints Solved Second pass at: Reading a trial's population section before its results Writing it up because I had to work it out twice and would rather nobody else did. Reading STEP 1 ( N Engl J Med , 2021) for the…		4	9.5k	10h